An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Latest Information Update: 05 Jul 2024
At a glance
- Drugs Bizaxofusp (Primary) ; Bizaxofusp (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Medicenna Therapeutics
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 24 Apr 2024 According to a Medicenna Therapeutics media release, data from this study will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago from May 31 -June 4, 2024
- 14 Feb 2024 According to a Medicenna Therapeutics media release, the company plans to seek to apply for Breakthrough Therapy Designation (BTD) for bizaxofusp based on compelling data from this trial presented at the SNO.